Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome

References

• Zhang H, Sturchler E, Zhu J, et al. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nat Commun. 2015;6:8918.
   PubMed Web of Science ®Google Scholar
• Bo A. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Manage. 2013;3(5):401–413.
   Google Scholar
• Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146–55.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021;131(2):e142243.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dulaglutide for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2017;17(4):485.
   PubMed Web of Science ®Google Scholar
• Zhong X, Chen Z, Chen Q, et al. Novel site-specific fatty chain-modified GLP-1 receptor agonist with potent antidiabetic effects. Molecules. 2019;24(4):779–789.
   PubMed Web of Science ®Google Scholar
• Rodbard HW. The clinical impact of GLP-1 receptor agonists in type 2 diabetes: focus on the long-acting analogs. Diabetes Technol Ther. 2018;20(S2):S233–S41.
   PubMedGoogle Scholar
• Samms RJ, Christe ME, Ruan X, et al. The dual GIP and GLP-1 receptor agonist tirzepatide regulates lipid and carbohydrate metabolism through GIPR in adipose tissue. Diabetes. 2019;68(Supplement 1): 1009–P.
   Google Scholar
• Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16(8):673–688.
   PubMed Web of Science ®Google Scholar
• Verge D, López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev. 2010;6(4):191–200.
   PubMedGoogle Scholar
• Chepurny OG, Matsoukas MT, Liapakis G, et al. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem. 2019;294(10):3514–3531.
   PubMed Web of Science ®Google Scholar
• Thompson A, Kanamarlapudi V. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway. Biochem Pharmacol. 2015;93(1):72–84.
   PubMed Web of Science ®Google Scholar
• Hager MV, Johnson LM, and Wootten D, et al. β-arrestin-biased agonists of the GLP-1 receptor from β-amino acid residue incorporation into GLP-1 analogues. J Am Chem Soc. 2016 138 45 ;jacs.6b08323.
   PubMed Web of Science ®Google Scholar
• Fang Z, Chen S, Manchanda Y, et al. Ligand-specific factors influencing GLP-1 receptor post-endocytic trafficking and degradation in pancreatic beta cells. Int J Mol Sci. 2020;21(21):8404.
   PubMed Web of Science ®Google Scholar
• Lei S, Clydesdale L, Dai A, et al. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. J Biol Chem. 2018;293(24):9370–9387.
   PubMed Web of Science ®Google Scholar
• Strandberg E, Kanithasen N, Tiltak D, et al. Solid-state NMR analysis comparing the designer-made antibiotic MSI-103 with its parent peptide PGLa in lipid bilayers. Biochemistry. 2008;47(8):2601–2616.
   PubMed Web of Science ®Google Scholar
• Wollheim CB, Meda P, Halban PA. Isolation of pancreatic islets and primary culture of the intact microorgans or of dispersed islet cells. Methods Enzymol. 1990;192:188–223.
   PubMed Web of Science ®Google Scholar
• Guo J, Li F, Qian S, et al. TGEV infection up-regulates FcRn expression via activation of NF-κB signaling. Sci Rep. 2016;6:32154.
   PubMed Web of Science ®Google Scholar
• Yang M, Hu Z, Yue R, et al. The efficacy and safety of qiming granule for dry eye disease: a systematic review and meta-analysis. Front Pharmacol. 2020;11:580.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Z, Wu W, et al. Effects of FM0807, a novel curcumin derivative, on lipopolysaccharide-induced inflammatory factor release via the ROS/JNK/p53 pathway in RAW264.7 cells. Biosci Rep. 2018;38(5):BSR20180849.
   PubMedGoogle Scholar
• Novikoff A, O’Brien SL, Bernecker M, et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab. 2021;49:101181.
   PubMed Web of Science ®Google Scholar
• Lu J, Willars GB. Endothelin-converting enzyme-1 regulates glucagon-like peptide-1 receptor signalling and resensitisation. Biochem J. 2019;476(3):513–533.
   PubMedGoogle Scholar
• Shaaban G, Oriowo M, and Al-Sabah S. Rate of homologous desensitization and internalization of the GLP-1 receptor. Molecules. 2016;22(1):22.
   PubMed Web of Science ®Google Scholar
• Fang Z, Chen S, Pickford P, et al. The influence of peptide context on signaling and trafficking of glucagon-like peptide-1 receptor biased agonists. ACS Pharmacol Transl Sci. 2020;3(2):345–360.
   PubMedGoogle Scholar
• Jones B, McGlone ER, Fang Z, et al. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors. J Biol Chem. 2021;296:100133.
   PubMed Web of Science ®Google Scholar
• Girada SB, Kuna RS, Bele S, et al. Gαs regulates glucagon-like peptide 1 receptor-mediated cyclic AMP generation at Rab5 endosomal compartment. Mol Metab. 2017;6(10):1173–1185.
   PubMed Web of Science ®Google Scholar